Recent Updates
Recently added Catalysts
COR Positive Sentiment Score: 70/100

Press Release

Key Takeaway: Cencora, Inc. has announced a share repurchase agreement with Walgreens Boots Alliance for approximately $50 million. This transaction coincides with Walgreens' sale of Cencora shares under Rule 144 of the Securities Act. The repurchased shares will be held in treasury, reflecting Cencora's commitment to capital management. Additionally, Walgreens continues to maintain a stake in Cencora, which remains pledged for other financial obligations. Cencora, a leading pharmaceutical solutions provider, emphasizes its role in enhancing healthcare access and outcomes globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cencora is actively managing its capital through share repurchase.
  • The company is strengthening its financial position by acquiring its shares.
  • Cencora's ranking among Fortune 500 companies highlights its market strength.
  • The firm has substantial annual revenue, reinforcing investor confidence.

CONCERNS & RISKS

  • Walgreens Boots Alliance is divesting a significant amount of its shares.
  • The need for repurchase indicates possible dilution concerns from the market.

Full Press Release Details

CENCORA ANNOUNCES COMMON SHARE REPURCHASE FROM WALGREENS BOOTS ALLIANCE
CONSHOHOCKEN, PA, February 6, 2025 - Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended.
Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury.
The sale of Cencora shares by Walgreens Boots Alliance is occurring simultaneously with the early settlement of certain previously disclosed variable prepaid forward sale contracts with financial institutions and the return of certain Cencora shares pledged to the financial institutions as security for those contracts. Walgreens Boots Alliance's remaining ownership of Cencora's common stock continues to be pledged to financial institutions to secure its obligations under other existing variable prepaid forward sale contracts.
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $290 billion in annual revenue.
Contacts: Bennett S. Murphy
Senior Vice President, Head of Investor Relations & Treasury
610-727-3693
Bennett.Murphy@cencora.com

Frequently Asked Questions

What share repurchase agreement did Cencora announce?

Cencora announced a $50 million share repurchase agreement with Walgreens Boots Alliance.

How much will Cencora pay per share for the repurchase?

Cencora will buy shares at the same price as in Walgreens Boots Alliance's Rule 144 sale.

What is Cencora's primary business focus?

Cencora focuses on improving lives by providing pharmaceutical solutions globally.

How many employees does Cencora have worldwide?

Cencora employs over 46,000 team members across the globe.

What is Cencora's ranking on the Fortune 500 list?

Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500.

Last updated: Feb 6, 2025